.SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) bit.ly/3wcnISX $SCYX

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem bit.ly/3wftZ06 $ITRM

Qpex Biopharma scientists will present microbiological data and Phase 1 results for oral xeruborbactam - the first orally bioavailable beta-lactamase inhibitor with inhibitory activity against both serine and metallo beta-lactamases.

As #AMR continues to grow the need for new & more effective antimicrobials remains paramount. We must fix the broken market and incentivize antimicrobial development to ensure our doctors are equipped with a full armamentarium to treat resistant infections bit.ly/3UeRsX3

CorMedix Inc. Announces CMS Grants TDAPA to Defencath bit.ly/4bpWUh5 $CRMD

Even with newer, more effective antibiotics on the market, clinicians continue to frequently treat #AMR infections with older generics due in part to a sizable disparity in costs, underscoring the significant need for reimbursement reform. bit.ly/3QbSaDn

.SCYNEXIS is committed to protecting the world against dangerous and difficult-to-treat infectious diseases. Learn about their next-generation triterpenoid antifungals here: bit.ly/3Y2cTMz $SCYX

.Melinta Therapeutics ’s portfolio includes commercial-stage antibiotics including Rezzayo, Kimyrsa, Vabomere, Orbactiv, Minocin, and Baxdela. Learn more: bit.ly/3bxywQB

The societal importance of antimicrobials, particularly those addressing #AMR , is not adequately recognized in the healthcare marketplace, leading to inadequate compensation. New pricing reimbursement pathways that better reflect their value are needed. bit.ly/3hepffp

.Crestone is focused on developing small molecule drugs for serious bacterial infections. Their R&D pipeline includes several programs that address areas of significant & growing unmet medical need, all with novel mechanism of action agents. bit.ly/3TpbCM7

#AntimicrobialResistance occurs when microorganisms change with exposure to antimicrobial drugs (such as antibiotics, antifungals and antivirals). Microorganisms that develop AMR are sometimes referred to as #superbugs . Learn more about #AMR here: bit.ly/3hepffp

Boulder, Colorado-based Crestone, Inc. is a clinical stage biopharmaceutical company focused on inventing and developing novel mechanism of action small molecule drugs for serious bacterial infections. Our pipeline includes antibacterial agents aiming to treat a variety of se ...

Our CEO Mike Dudley joined a roundtable of experts to discuss the importance of changes in policy and where he emphasized the importance of application of new improved methods to show value of antibiotics. No Patient Left Behind CARB-X SIDP Global Antibiotic R&D Partnership (GARDP) IDSA Antimicrobials Working Group Shionogi Inc. (U.S.)

Iterum is developing sulopenem - the first oral and IV penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative infections in both the hospital and community settings. Learn more: bit.ly/2ITdETx $ITRM

.SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update bit.ly/4aAMivl $SCYX

Antimicrobial resistant infections can be difficult, and sometimes impossible, to treat. Learn more about #AntimicrobialResistance , one of the most urgent threats to public health, from the CDC: bit.ly/32GpgoT #AMR

CorMedix is developing and commercializing innovative therapeutic products for the prevention and treatment of life-threatening conditions including Catheter-related blood stream infections (CRBSIs). Learn more about CRBSIs in patients with HD-CVC here: bit.ly/43dLTMV

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 bit.ly/3PzzWeS $ITRM